F-1/A: Anew Health IPO Faces Headwinds Amid Profit Decline

Anew Health Limited, a Hong Kong-based pain management and health services provider, is launching an initial public offering on Nasdaq Capital Market despite a 53% decrease in net income and a working capital deficit.

Summary

• Anew Health Limited is offering 1,800,000 Ordinary Shares in an initial public offering (IPO) with an expected price range of US$4.00 to US$6.00 per share.
• The company has applied to list its Ordinary Shares on the Nasdaq Capital Market under the symbol AVG.
• Anew Health is a Cayman Islands holding company that conducts all operations through its Hong Kong-based subsidiaries, VG Zenith and Victor Zenith.
• The company provides non-surgical, non-invasive, and non-pharmacological pain management and functional enhancement therapies under its ANKH brand, combining Traditional Chinese Medicine (TCM) wisdom with energy-based treatment devices.
• It also sells topical use and dietary supplement health products through its service centers and online shop.
• Anew Health operates three service centers in prime commercial buildings in Hong Kong.
• The number of clients served increased from 8,692 in FY2024 to 10,039 in FY2025, with average annual spending per client rising 3.2% to US$6,478 in FY2025.
• Total revenue for the year ended March 31, 2025, was approximately US$40.0 million, a 1.9% decrease from US$40.8 million in FY2024.
• Net income for FY2025 was approximately US$5.5 million, representing a significant 53% decrease from US$11.7 million in FY2024.
• The decrease in net income is primarily attributed to increased cost of revenue (US$1.9 million increase), marketing expenses, and general and administrative expenses (US$3.6 million increase, including a one-off discretionary bonus to senior management).
• As of March 31, 2025, the company had a working capital deficit of US$7,827,815, which its auditor, WWC, P.C., noted raises substantial doubt about its ability to continue as a going concern.
• The estimated net proceeds from the IPO, assuming a US$4.00 per share price, are approximately US$4.75 million, after deducting underwriting discounts and estimated offering expenses of US$2,445,099.
• Proceeds are planned for research and development (20%), establishing a new service center in Hong Kong (30%), establishing new international service centers (25%), enhancing IT systems (10%), and general working capital (15%).

Sentiment

Score: 3

Explanation: While the company operates in a growing market and has a recognized brand, the significant decline in net income, revenue decrease, and substantial working capital deficit, coupled with the auditor's going concern warning, indicate considerable financial distress and high risk for investors. The IPO proceeds are crucial for its survival and growth plans, but the underlying financial health is weak.

Positives

• The company operates under a reputable ANKH brand with over 16 years of experience in pain management and functional enhancement.
• High customer satisfaction rates were reported in an internal survey: 81.7% overall satisfaction, 87.8% satisfaction with trained therapists, and 69.4% reported pain symptom reduction.
• The client base grew from 8,692 in FY2024 to 10,039 in FY2025, and average annual spending per client increased by 3.2% to US$6,478 in FY2025.
• Offers a broad range of non-surgical, non-invasive, and non-pharmacological treatments, combining Traditional Chinese Medicine with advanced energy-based devices.
• The non-pharmacological pain management market in Hong Kong is projected to grow at an 8.7% CAGR in sales value from 2023 to 2025, driven by an aging population and increasing health awareness.
• The company's auditor, WWC, P.C., is headquartered in California and subject to PCAOB inspections, not affected by the 2020/2021 PCAOB determinations regarding China/Hong Kong firms.

Negatives

• Net income decreased significantly by 53% from US$11.7 million in FY2024 to US$5.5 million in FY2025.
• Total revenue slightly decreased by 1.9% from US$40.8 million in FY2024 to US$40.0 million in FY2025.
• The company had a working capital deficit of US$7,827,815 as of March 31, 2025, raising substantial doubt about its ability to continue as a going concern.
• Cost of revenue increased by 16.8% (US$1.9 million) primarily due to higher personnel costs.
• General and administrative expenses increased by 46.8% (US$3.6 million), driven by senior management compensation, a one-off discretionary bonus, and new treatment center costs.
• The company relies on a single geographical market (Hong Kong), exposing it to local economic, social, and political risks.
• No long-term supply agreements are in place with suppliers of treatment devices, posing potential supply chain risks.
• The company does not maintain product liability insurance, which could expose it to substantial financial and reputational damage from claims.
• Management team lacks experience in managing a U.S. public company and complying with associated regulatory obligations.
• Anew Health will be a 'controlled company' post-IPO, with AW Ocean Limited owning 96.53% of voting power, potentially allowing reliance on corporate governance exemptions.
• There is no present plan to declare or pay any dividends on Ordinary Shares in the foreseeable future.
• The company may experience extreme stock price volatility due to its relatively small public float and large insider holdings.

Risks

• The working capital deficit as of March 31, 2025, raises substantial doubt about the Company's ability to continue as a going concern.
• Significant variability in operating results due to increased operating expenses and cost of revenue could adversely affect profitability.
• Unfavorable publicity or consumer perception could negatively affect the company's reputation and business performance.
• Customer complaints, claims, and legal proceedings in the regular course of operations could result in significant costs and harm brand image.
• Failure to maintain the quality of equipment, treatment devices, supplies, and products could expose the company to liabilities and damage its reputation.
• Reliance on third-party suppliers, including limited source suppliers, for products and treatment devices could lead to lost revenue if they fail to produce on time or to specifications.
• Lack of long-term supply agreements with treatment device suppliers could lead to decreased supply, increased costs, or quality deterioration.
• Inherent risks relating to product liability claims or product recalls could cause significant expenses and damages, especially without product liability insurance.
• Inability to hire and retain qualified personnel (consultants, therapists, management) could adversely affect service quality, brand image, and business strategy.
• Intense competition in the pain management and health industry could lead to loss of market share and reduced profitability.
• If the market for products and services does not continue to grow as expected, business, financial condition, and operating results may be adversely affected.
• Reliance on a single geographical market (Hong Kong) exposes the business to adverse economic, social, and political conditions.
• Introduction of disruptive technological breakthroughs (energy-based, pharmaceutical, or other) could present challenges to operations and success.
• Newly opened and acquired service centers may not achieve anticipated operating results, materially affecting operations.
• Dependence on the continued services of certain key personnel; loss of their services would greatly harm the business.
• Management team lacks experience in managing a U.S. public company and complying with applicable laws.
• Failure to effectively maintain, promote, and enhance the brand in a cost-effective manner could harm business and competitive advantage.
• Any substantial increase in rent or non-renewal of lease agreements may affect operations and financial condition.
• Cybersecurity risks, breaches, and other disruptions could compromise customer data, damage reputation, and expose the company to liability.
• Occurrence of force majeure events, natural disasters, pandemic outbreaks, terrorist acts, and global political events could disrupt operations and financial performance.
• Business involves significant risks and uncertainties that may not be covered by insurance.
• The PRC government may exercise significant direct oversight and discretion over Hong Kong operations, potentially resulting in material changes to operations or share value.
• Uncertainties exist regarding future requirements for PRC approvals to list on U.S. exchanges and offer securities, and compliance with data security laws.
• The enforcement of laws and regulations in the PRC and Hong Kong can change quickly with little advance notice, limiting legal protections.
• The Hong Kong National Security Law could impact Hong Kong subsidiaries, which represent substantially all of the business.
• Political risks are associated with conducting business in Hong Kong.
• Changes in currency conversion rates between Hong Kong dollar and U.S. dollar may affect the value of investments.
• Corporate actions will be substantially controlled by AW Ocean Limited, which may deprive other shareholders of a premium for their shares.
• Reliance on dividends and other distributions from subsidiaries to fund cash requirements, which could be restricted by PRC government intervention.
• Enforcement of foreign civil liabilities in the Cayman Islands and Hong Kong is subject to certain conditions, making U.S. judgments difficult to enforce.
• Difficulties in protecting interests through U.S. courts may be limited due to incorporation under Cayman Islands law.
• No public market for Ordinary Shares prior to this offering, and no assurance of a liquid public market developing.
• Extreme stock price volatility unrelated to actual or expected operating performance, financial condition, or prospects.
• Ordinary Shares may be thinly traded, making it difficult to sell at or near ask prices or at all.
• Investors purchasing Ordinary Shares in this offering will incur immediate and substantial dilution in the book value of their shares.
• Sale or availability for sale of substantial amounts of Ordinary Shares in the public market could adversely affect the market price.
• If securities or industry analysts do not publish research or reports, or publish negative reports, the price and trading volume could decline.
• Broad discretion in the use of net proceeds from this offering, which may not be used effectively.
• Nasdaq may apply additional and more stringent criteria for initial and continued listing due to a small public offering and large insider holdings.
• Failure to satisfy Nasdaq Capital Market listing requirements could lead to delisting.
• As an emerging growth company, reduced disclosure requirements may make Ordinary Shares less attractive to investors.
• As a foreign private issuer, the company is exempt from certain provisions applicable to U.S. domestic public companies, potentially affording less protection to shareholders.
• As a Cayman Islands company, certain corporate governance practices may differ significantly from Nasdaq listing standards.
• Loss of foreign private issuer status in the future could result in significant additional costs and expenses.
• Increased costs as a public company, particularly after ceasing to qualify as an emerging growth company.
• Reliance on price appreciation of Ordinary Shares for investment return, as dividends are not planned.
• There is no assurance that the company will not be a passive foreign investment company (PFIC) for U.S. federal income tax purposes, which could subject U.S. investors to significant adverse tax consequences.

Future Outlook

The company plans to drive organic growth by expanding its customer base and service center network in Hong Kong, enhancing brand awareness, and strategically expanding into selected global markets such as Singapore, Malaysia, Japan, South Korea, Canada, and the United States. It intends to maintain and enhance the professional expertise of its frontline staff and broaden its treatment services and product offerings. A significant focus is on substantially enhancing research and development capabilities, including establishing a specialized R&D department in Q1 2025, to develop and commercialize portable energy-based at-home treatment devices, with prototypes expected in early 2026 and market readiness by the end of 2026.

Management Comments

• "ANKH, stands for A New Key to Health, testifying our aspiration to be a health brand not only for alleviating physical pain but also for allowing individuals to emanate joy, health, and vitality from within and throughout."
• "We believe that our professional services, proven approach to pain management, and capability to offer a broad range of treatment services and products have enabled us to offer our clients distinguished experience at our service centers."
• "We believe that our current cash and cash equivalents, anticipated cash flow from operations, available credit facilities, and the proceeds from this offering will be sufficient to meet our anticipated cash needs, including our cash needs for working capital and capital expenditures, for at least the next 12 months."

Industry Context

The non-pharmacological pain management market in Hong Kong is experiencing significant growth, driven by an aging population, increasing awareness of chronic pain, and a rising preference for non-pharmaceutical treatment options. The market's sales value is projected to increase from approximately HKD 6,674 million in 2023 to HKD 7,882 million in 2025, reflecting an 8.7% CAGR. The prevalence of musculoskeletal conditions, exacerbated by an aging demographic and post-COVID-19 symptoms, creates substantial unmet needs. Health institutions are increasingly valuing non-pharmacological methods, with initiatives like the 'Confront Pain with Ease Project' supporting innovative treatments. The industry is competitive and fragmented, with a shift towards multidisciplinary management and personalized care, but faces challenges from new entrants, limited talent, and increasing operational costs.

Comparison to Industry Standards

• The company is ranked No. 3 in terms of average spending per customer in the non-pharmacological pain management services market in Hong Kong.
• The company is ranked No. 4 in customer experience trails in the non-pharmacological pain management services market in Hong Kong.
• The non-pharmacological pain management market in Hong Kong is projected to reach approximately HKD 7,882 million in sales value of services in 2025, compared to HKD 3,207 million in 2012, with a CAGR of 7.2%.
• The market witnessed rapid growth from 2019 to 2023, with a CAGR of 18.5% in the sales value of services, partly due to COVID-19.
• Hong Kong's population aged 65 and over is expected to increase from 1.5 million (20% of total) in 2021 to 2.52 million (31%) in 2039, indicating a strong demographic tailwind for pain management services.
• Total public and private health expenditure in Hong Kong in 2022-23 was approximately HK$284.1 billion, accounting for 10% of GDP, suggesting a robust and growing healthcare investment environment.

Management Changes

Corporate Governance

Legal Proceedings

• As of the date of the prospectus, the company had not been involved in any legal proceedings, investigations, or claims, nor was it aware of any pending or threatened litigation, arbitration, or other claims that would have a material adverse impact on its operations, financial position, and reputation.

Related Party Transactions

• On September 27, 2024, Anew Health declared a dividend of US$10,740,727 to AW Ocean Limited, the Controlling Shareholder, to partially set off amounts due from Mr. Ka Wai Victor, MO (Chief Executive Officer and Chairman of the Board).
• Amounts due from Mr. Ka Wai Victor, MO, a shareholder and executive officer, were US$1,073,723 as of March 31, 2024, which were fully repaid in cash on November 7, 2024. This was an unsecured, interest-free personal loan for investment purposes without a written agreement.
• Amounts due to Mr. Ka Wai Victor, MO, a shareholder and executive officer, were US$139,968 as of March 31, 2025, representing operational expenses paid by Mr. Mo on behalf of VG Zenith. This amount is unsecured, interest-free, and without specific repayment terms or written agreements.
• Salary compensation paid by Operating Subsidiaries to Mr. Ka Wai Victor, MO was US$2,526,629 for FY2025, compared to US$563,863 for FY2024.
• Salary compensation paid by Operating Subsidiaries to Ms. Sum Lok, CHEUNG, a director and spouse of Mr. Mo, was US$603,105 for FY2025, compared to US$236,689 for FY2024.
• Contributions to the Mandatory Provident Fund (MPF) for directors and executive officers totaled US$6,929 for FY2025 and US$6,901 for FY2024.

Stakeholder Impact

• Shareholders face significant risk of dilution from the IPO and potential loss of investment due to the company's going concern warning and financial performance. The controlling shareholder's majority ownership limits the influence of public shareholders.
• Employees, particularly operations and support personnel, have seen increased headcount and senior management received significant bonuses and payroll adjustments, indicating growth in staffing and compensation.
• Customers may benefit from the company's expansion plans, including new service centers and diversified offerings, but face risks related to service quality if qualified personnel cannot be retained.
• Suppliers face risks due to the absence of long-term supply agreements, potentially leading to instability in demand or pricing.
• Creditors may face increased risk due to the company's working capital deficit and the auditor's going concern warning, which could impact the company's ability to meet its obligations.

Next Steps

• Complete the listing of Ordinary Shares on the Nasdaq Capital Market under the symbol AVG.
• Expand the customer base and network of service centers in Hong Kong.
• Strategically expand market coverage into selected global markets (Singapore, Malaysia, Japan, South Korea, Canada, United States).
• Maintain and enhance the professional expertise of frontline staff through ongoing training and assessment.
• Develop and broaden the variety of treatment services and product offerings, including diversifying topical use and dietary supplement product lines.
• Establish a specialized research and development department in Q1 2025.
• Develop and commercialize portable energy-based at-home treatment devices, with a prototype expected in early 2026 and market readiness by the end of 2026.
• Recruit highly trained professionals and industry experts for the R&D department.
• Maintain and strengthen dialogue and collaboration with global experts in the pain management field.
• Potentially explore technological expansions through mergers and acquisitions of assets, patents, technologies, or manufacturing capabilities.

Key Dates

Recommendation

The company presents a high-risk investment due to a substantial 53% decline in net income, a slight revenue decrease, and a significant working capital deficit that led its auditor to raise "substantial doubt about the Company's ability to continue as a going concern." While the IPO aims to raise capital for expansion and R&D, the underlying financial instability and operational challenges, including increased costs and reliance on a single market, outweigh the positives of market growth and brand recognition. The high concentration of ownership by a controlling shareholder also limits public investor influence. Investors should be wary of the significant risks, including potential loss of entire investment, and consider selling or avoiding this stock.

Keywords

pain management, health services, Hong Kong, IPO, Nasdaq, Traditional Chinese Medicine, TCM, energy-based treatment, wellness, healthcare products, ANKH, SEC filing, F-1/A, Cayman Islands, corporate governance, risk factors, financial performance, going concern, public offering, cybersecurity, data privacy, PRC regulation